Potency and Breadth of Neutralization after 3 doses of mRNA vaccines in COVID-19 Convalescent and Naïve individuals

  1. Joanna Luczkowiak
  2. Gonzalo Rivas
  3. Nuria Labiod
  4. Fátima Lasala
  5. Marta Rolo
  6. Jaime Lora-Tamayo
  7. Mikel Mancheno-Losa
  8. David Rial-Crestelo
  9. Alfredo Pérez-Rivilla
  10. María D. Folgueira
  11. Rafael Delgado

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

Third doses of mRNA COVID-19 vaccines induced a significant increase in neutralizing potency and breadth in naïve individuals comparable with convalescents who restored levels after the first two doses. These results suggest a limit to elicit neutralization in the number of stimuli by infection or vaccination with ancestral SARS-CoV-2 sequences

Article activity feed

  1. ScreenIT

    SciScore for 10.1101/2022.03.17.22272557: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsConsent: cohort, IRB approval ref CEIm 20/157) and were recruited after informed consent and randomly selected among those with serum samples available for the study period.
    Sex as a biological variablenot detected.
    Randomizationcohort, IRB approval ref CEIm 20/157) and were recruited after informed consent and randomly selected among those with serum samples available for the study period.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    RBD-binding antibodies: Anti-RBD Ig titers were determined by an electrochemiluminescence commercial assay (Elecsys Anti-SARS-CoV-2, Roche Diagnostics, Basel, Switzerland) and were converted to WHO International Standard Binding Antibody Units and expressed as BAU/mL following the manufacturer instructions
    Anti-RBD
    suggested: None
    Anti-SARS-CoV-2
    suggested: None
    Recombinant DNA
    SentencesResources
    Spike sequences from SARS-CoV-2 variant Alpha (B.1.1.7, GISAID: EPI_ISL_608430), SARS-CoV-2 variant Beta (B.1.351, GISAID: EPI_ISL_712096), SARS-CoV-2 variant Gamma (P.1, GISAID: EPI_ISL_833140), SARS-CoV-2 variant Delta (B.1.617.2, GISAID: EPI_ISL_1970335) and SARS-CoV-2 variant Omicron (B.1.1.529, GISAID: EPI_ISL_6640917) were synthesized and cloned into pcDNA3.1 by GeneArt technology (Thermo Fisher Scientific GENEART GmbH, Regensburg, Germany).
    pcDNA3.1
    suggested: RRID:Addgene_79663)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  2. Version published to 10.1101/2022.03.17.22272557v1 on medRxiv